CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes
Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
Standard
CVOT Summit 2022 Report : new cardiovascular, kidney, and glycemic outcomes. / Schnell, Oliver; Battelino, Tadej; Bergenstal, Richard; Birkenfeld, Andreas L.; Ceriello, Antonio; Cheng, Alice; Davies, Melanie; Edelman, Steve; Forst, Thomas; Giorgino, Francesco; Green, Jennifer; Groop, Per Henrik; Hadjadj, Samy; J.L.Heerspink, Hiddo; Hompesch, Marcus; Izthak, Baruch; Ji, Linong; Kanumilli, Naresh; Mankovsky, Boris; Mathieu, Chantal; Miszon, Martin; Mustafa, Reem; Nauck, Michael; Pecoits-Filho, Roberto; Pettus, Jeremy; Ranta, Kari; Rodbard, Helena W.; Rossing, Peter; Ryden, Lars; Schumm-Draeger, Petra Maria; Solomon, Scott D.; Škrha, Jan; Topsever, Pinar; Vilsbøll, Tina; Wilding, John; Standl, Eberhard.
I: Cardiovascular Diabetology, Bind 22, Nr. 1, 59, 2023.Publikation: Bidrag til tidsskrift › Kommentar/debat › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - CVOT Summit 2022 Report
T2 - new cardiovascular, kidney, and glycemic outcomes
AU - Schnell, Oliver
AU - Battelino, Tadej
AU - Bergenstal, Richard
AU - Birkenfeld, Andreas L.
AU - Ceriello, Antonio
AU - Cheng, Alice
AU - Davies, Melanie
AU - Edelman, Steve
AU - Forst, Thomas
AU - Giorgino, Francesco
AU - Green, Jennifer
AU - Groop, Per Henrik
AU - Hadjadj, Samy
AU - J.L.Heerspink, Hiddo
AU - Hompesch, Marcus
AU - Izthak, Baruch
AU - Ji, Linong
AU - Kanumilli, Naresh
AU - Mankovsky, Boris
AU - Mathieu, Chantal
AU - Miszon, Martin
AU - Mustafa, Reem
AU - Nauck, Michael
AU - Pecoits-Filho, Roberto
AU - Pettus, Jeremy
AU - Ranta, Kari
AU - Rodbard, Helena W.
AU - Rossing, Peter
AU - Ryden, Lars
AU - Schumm-Draeger, Petra Maria
AU - Solomon, Scott D.
AU - Škrha, Jan
AU - Topsever, Pinar
AU - Vilsbøll, Tina
AU - Wilding, John
AU - Standl, Eberhard
N1 - Publisher Copyright: © 2023, The Author(s).
PY - 2023
Y1 - 2023
N2 - The 8th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Kidney, and Glycemic Outcomes was held virtually on November 10–12, 2022. Following the tradition of previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed outcomes trials as well as key trials important to the cardiovascular (CV) field. This year’s focus was on the results of the DELIVER, EMPA-KIDNEY and SURMOUNT-1 trials and their implications for the treatment of heart failure (HF) and chronic kidney disease (CKD) with sodium-glucose cotransporter-2 (SGLT2) inhibitors and obesity with glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. A broad audience of primary care physicians, diabetologists, endocrinologists, cardiologists, and nephrologists participated online in discussions on new consensus recommendations and guideline updates on type 2 diabetes (T2D) and CKD management, overcoming clinical inertia, glycemic markers, continuous glucose monitoring (CGM), novel insulin preparations, combination therapy, and reclassification of T2D. The impact of cardiovascular outcomes on the design of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) trials, as well as the impact of real-world evidence (RWE) studies on the confirmation of CVOT outcomes and clinical trial design, were also intensively discussed. The 9th Cardiovascular Outcome Trial Summit will be held virtually on November 23–24, 2023 (http://www.cvot.org).
AB - The 8th Cardiovascular Outcome Trial (CVOT) Summit on Cardiovascular, Kidney, and Glycemic Outcomes was held virtually on November 10–12, 2022. Following the tradition of previous summits, this reference congress served as a platform for in-depth discussion and exchange on recently completed outcomes trials as well as key trials important to the cardiovascular (CV) field. This year’s focus was on the results of the DELIVER, EMPA-KIDNEY and SURMOUNT-1 trials and their implications for the treatment of heart failure (HF) and chronic kidney disease (CKD) with sodium-glucose cotransporter-2 (SGLT2) inhibitors and obesity with glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonists. A broad audience of primary care physicians, diabetologists, endocrinologists, cardiologists, and nephrologists participated online in discussions on new consensus recommendations and guideline updates on type 2 diabetes (T2D) and CKD management, overcoming clinical inertia, glycemic markers, continuous glucose monitoring (CGM), novel insulin preparations, combination therapy, and reclassification of T2D. The impact of cardiovascular outcomes on the design of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) trials, as well as the impact of real-world evidence (RWE) studies on the confirmation of CVOT outcomes and clinical trial design, were also intensively discussed. The 9th Cardiovascular Outcome Trial Summit will be held virtually on November 23–24, 2023 (http://www.cvot.org).
KW - Cardiovascular disease
KW - Chronic kidney disease
KW - Diabetes
KW - GIP/GLP-1 receptor agonist
KW - Heart failure
KW - Obesity
KW - SGLT2 inhibitor
U2 - 10.1186/s12933-023-01788-6
DO - 10.1186/s12933-023-01788-6
M3 - Comment/debate
C2 - 36927451
AN - SCOPUS:85150314857
VL - 22
JO - Cardiovascular Diabetology
JF - Cardiovascular Diabetology
SN - 1475-2840
IS - 1
M1 - 59
ER -
ID: 344645953